 | Up a level |
2018
Heidenreich, A., Carl, S., Feyerabend, S., Gleissner, J., Gruellich, C., Heinrich, B., Merseburger, A., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Go, J., Golsorkhi, T., Abida, W. and Scher, H. I. (2018). TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 75 - 76. BASEL: KARGER. ISSN 2296-5262
Merseburger, A., Carl, S., Feyerabend, S., Gleissner, J., Grimm, M. -O., Gruellich, C., Heidenreich, A., Heinrich, B., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Passler, L., Shetty, S., Golsorkhi, T., Ryan, C. and Chowdhury, S. (2018). TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 74 - 75. BASEL: KARGER. ISSN 2296-5262